Emergent Biosolutions (EBS) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Emergent Biosolutions is set to announce its Q2 2025 earnings on August 6th, expecting earnings of $0.21 per share and revenue of $148.55 million.
• Shares of EBS recently opened at $6.50, down 4.2%, with a market capitalization of $352.54 million.
• Institutional investors own 78.40% of Emergent Biosolutions, with Millennium Management recently increasing its stake by 68.9%.

Emergent Biosolutions (NYSE:EBS - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.21 per share and revenue of $148.55 million for the quarter. Emergent Biosolutions has set its FY 2025 guidance at EPS.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.22. The business had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. Emergent Biosolutions had a negative return on equity of 0.52% and a negative net margin of 13.63%. On average, analysts expect Emergent Biosolutions to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Emergent Biosolutions Trading Down 4.3%

Emergent Biosolutions stock traded down $0.25 during mid-day trading on Friday, hitting $5.63. The stock had a trading volume of 1,470,301 shares, compared to its average volume of 1,221,635. The company has a current ratio of 6.32, a quick ratio of 3.51 and a debt-to-equity ratio of 1.20. Emergent Biosolutions has a 12 month low of $4.02 and a 12 month high of $13.28. The stock has a market capitalization of $305.60 million, a PE ratio of -2.08 and a beta of 2.09. The stock has a 50-day simple moving average of $6.68 and a two-hundred day simple moving average of $6.81.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, Director Keith Katkin sold 7,844 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $6.30, for a total transaction of $49,417.20. Following the transaction, the director owned 86,431 shares in the company, valued at approximately $544,515.30. This trade represents a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company's stock.

Hedge Funds Weigh In On Emergent Biosolutions

An institutional investor recently raised its position in Emergent Biosolutions stock. Goldman Sachs Group Inc. increased its holdings in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 12.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,090,655 shares of the biopharmaceutical company's stock after purchasing an additional 121,583 shares during the period. Goldman Sachs Group Inc. owned approximately 2.01% of Emergent Biosolutions worth $5,301,000 at the end of the most recent quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.